Freezing shock monocytes deliver antisense oligonucleotides via liposomes for the treatment of idiopathic pulmonary fibrosis

Hailong Li , Xi Wu , Jinhe Li , Liqing Han , Hongting Liu , Qiuyan Jiang , Bowen Liu , Qin Xia , Zherui Li , Xiaohe Li , Songtao Gu , Aiguo Xu , Honggang Zhou , Xiaoting Gu , Zuojun Xu , Xiaoyu Ai , Cheng Yang

Asian Journal of Pharmaceutical Sciences ›› 2026, Vol. 21 ›› Issue (1) : 101128

PDF (4776KB)
Asian Journal of Pharmaceutical Sciences ›› 2026, Vol. 21 ›› Issue (1) :101128 DOI: 10.1016/j.ajps.2026.101128
Research Article
research-article
Freezing shock monocytes deliver antisense oligonucleotides via liposomes for the treatment of idiopathic pulmonary fibrosis
Author information +
History +
PDF (4776KB)

Abstract

Connective tissue growth factor (CTGF) is a key driver in the pathogenesis of idiopathic pulmonary fibrosis (IPF). This study presents a groundbreaking supramolecular cryo-shock bone marrow mononuclear cell system for targeted drug delivery in IPF. We incorporated antisense oligonucleotides (ASO) to inhibit CTGF and simultaneously encapsulated nintedanib using the ZMO-E5-NPs carrier for synergistic delivery. The cryo-shock treatment enhances cellular structural integrity and preserves receptor functionality, thereby extending cell viability. By modifying the E5 peptide and conjugating it with DSPE-PEG-MAL, we developed a composite carrier, ZMO-E5-NPs, which demonstrates efficient lung-targeting capability. This system enables rapid nanoparticle capture by fibroblasts through matrix metalloproteinase 2 (MMP2) recognition, ensuring precise delivery of both ASO and nintedanib. In a bleomycin-induced pulmonary fibrosis mouse model, ZMO-E5-NPs-ASO (nintedanib-containing group) significantly attenuated fibrosis progression, improved lung function, and exhibited excellent biocompatibility and safety, highlighting its potential as a novel therapeutic strategy for respiratory diseases.

Keywords

Connective tissue growth factor / Idiopathic pulmonary fibrosis / Antisense oligonucleotides / Nintedanib / Matrix metalloproteinase 2 / Lung function

Cite this article

Download citation ▾
Hailong Li, Xi Wu, Jinhe Li, Liqing Han, Hongting Liu, Qiuyan Jiang, Bowen Liu, Qin Xia, Zherui Li, Xiaohe Li, Songtao Gu, Aiguo Xu, Honggang Zhou, Xiaoting Gu, Zuojun Xu, Xiaoyu Ai, Cheng Yang. Freezing shock monocytes deliver antisense oligonucleotides via liposomes for the treatment of idiopathic pulmonary fibrosis. Asian Journal of Pharmaceutical Sciences, 2026, 21 (1) : 101128 DOI:10.1016/j.ajps.2026.101128

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Bonella F, Spagnolo P, Ryerson C. Current and future treatment landscape for idiopathic pulmonary fibrosis. Drugs 2023; 83: 1581-93.

[2]

Podolanczuk AJ, Thomson CC, Remy-Jardin M, Richeldi L, Martinez FJ, Kolb M, et al. Idiopathic pulmonary fibrosis: state of the art for 2023. Eur Respir J 2023; 61(4): 2200957.

[3]

Gan C, Wang Y, Xiang Z, Liu H, Tan Z, Xie Y, et al. Niclosamide-loaded nanoparticles (Ncl-NPs) reverse pulmonary fibrosis in vivo and in vitro . J Adv Res 2023; 51: 109-20.

[4]

Kim JS, Murray S, Yow E, Anstrom KJ, Kim HJ, Flaherty KR, et al. Comparison of pirfenidone and nintedanib: post hoc analysis of the CleanUP-IPF study. Chest 2024; 165: 1163-73.

[5]

John AE, Joseph C, Jenkins G, Tatler AL. COVID-19 and pulmonary fibrosis: a potential role for lung epithelial cells and fibroblasts. Immunol Rev 2021; 302: 228-40.

[6]

Li Z, Niu S, Guo B, Gao T, Wang L, Wang Y, et al. Stem cell therapy for COVID-19, ARDS and pulmonary fibrosis. Cell Prolif 2020; 53: e12939.

[7]

Enomoto Y, Katsura H, Fujimura T, Ogata A, Baba S, Yamaoka A, et al. Autocrine TGF- β-positive feedback in profibrotic AT2-lineage cells plays a crucial role in non-inflammatory lung fibrogenesis . Nat Commun 2023; 14: 4956.

[8]

Guan R, Yuan L, Li J, Wang J, Li Z, Cai Z, et al. Bone morphogenetic protein 4 inhibits pulmonary fibrosis by modulating cellular senescence and mitophagy in lung fibroblasts. Eur Respir J 2022; 60(6): 2102307.

[9]

Hayek H, Rehbini O, Kosmider B, Brandt T, Chatila W, Marchetti N, et al. The regulation of fatty acid synthase by exosomal miR-143-5p and miR-342-5p in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2024; 70: 259-82.

[10]

Effendi WI, Nagano T. Connective tissue growth factor in idiopathic pulmonary fibrosis: breaking the bridge. Int J Mol Sci 2022; 23(11): 6064.

[11]

Richeldi L, Fernández Pérez ER, Costabel U, Albera C, Lederer DJ, Flaherty KR, et al. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2020; 8: 25-33.

[12]

Leask A. Breathe, breathe in the air: the anti-CCN2 antibody pamrevlumab (FG-3019) completes a successful phase II clinical trial for idiopathic pulmonary fibrosis. J Cell Commun Signal 2019; 13: 441-2.

[13]

Egli M, Manoharan M. Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Res 2023; 51: 2529-73.

[14]

Sergeeva OV, Shcherbinina EY, Shomron N, Zatsepin TS. Modulation of RNA splicing by oligonucleotides: mechanisms of action and therapeutic implications. Nucleic Acid Ther 2022; 32: 123-38.

[15]

Crooke ST, Baker BF, Crooke RM, Liang XH. Antisense technology: an overview and prospectus. Nat Rev Drug Discov 2021; 20: 427-53.

[16]

Kulkarni JA, Witzigmann D, Thomson SB, Chen S, Leavitt BR, Cullis PR, et al. The current landscape of nucleic acid therapeutics. Nat Nanotechnol 2021; 16: 630-43.

[17]

Liu F, Xin M, Feng H, Zhang W, Liao Z, Sheng T, et al. Cryo-shocked tumor cells deliver CRISPR-Cas9 for lung cancer regression by synthetic lethality. Sci Adv 2024; 10: eadk8264.

[18]

Xu X, Kwong CHT, Li J, Wei J, Wang R. Zombie" macrophages for targeted drug delivery to treat acute pneumonia. ACS Appl Mater Interfaces 2023; 15: 29012-22.

[19]

Wu L, Du Z, Li L, Qiao L, Zhang S, Yin X, et al. Camouflaging attenuated Salmonella by cryo-shocked macrophages for tumor-targeted therapy. Sign Transd Target Ther 2024; 9: 14.

[20]

Rinaldi C, Wood MJA. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol 2018; 14: 9-21.

[21]

Booth BJ, Nourreddine S, Katrekar D, Savva Y, Bose D, Long TJ, et al. RNA editing: expanding the potential of RNA therapeutics. Mol Ther 2023; 31: 1533-49.

[22]

Logtenberg MEW, Scheeren FA, Schumacher TN. The CD47-sirp α immune checkpoint . Immunity 2020; 52: 742- 52.

[23]

Gallo J, Kamaly N, Lavdas I, Stevens E, Nguyen QD, Wylezinska-Arridge M, et al. CXCR4-targeted and MMP-responsive iron oxide nanoparticles for enhanced magnetic resonance imaging. Angew Chem Int Ed Engl 2014; 53(36): 9550-4.

[24]

Kassassir H, Papiewska-Pajak I, Kryczka J, Boncela J, Kowalska MA. Platelet-derived microparticles stimulate the invasiveness of colorectal cancer cells via the p38MAPK-MMP-2/MMP-9 axis. Cell Commun Signal 2023; 21: 51.

[25]

Della Latta V, Cecchettini A, Del Ry S, Morales MA. Bleomycin in the setting of lung fibrosis induction: from biological mechanisms to counteractions. Pharmacol Res 2015; 97: 122-30.

[26]

Wind S, Schmid U, Freiwald M, Marzin K, Lotz R, Ebner T, et al. Clinical pharmacokinetics and pharmacodynamics of nintedanib. Clin Pharmacokinet 2019; 58: 1131-47.

[27]

Pan L, Cheng Y, Yang W, Wu X, Zhu H, Hu M, et al. Nintedanib ameliorates bleomycin-induced pulmonary fibrosis, inflammation, apoptosis, and oxidative stress by modulating the PI3K/Akt/mTOR pathway in mice. Inflammation 2023;46:1531-42.

[28]

Gao S, Li X, Jiang Q, Liang Q, Zhang F, Li S, et al. PKM2 promotes pulmonary fibrosis by stabilizing TGF- β1 receptor I and enhancing TGF- β1 signaling . Sci Adv 2022; 8: eabo0987.

[29]

Petersen M, Wengel J. LNA: a versatile tool for therapeutics and genomics. Trends Biotechnol 2003; 21: 74-81.

[30]

Shadid M, Badawi M, Abulrob A. Antisense oligonucleotides: absorption, distribution, metabolism, and excretion. Expert Opin Drug Metab Toxicol 2021; 17: 1281-92.

[31]

Song S, Fu Z, Guan R, Zhao J, Yang P, Li Y, et al. Intracellular hydroxyproline imprinting following resolution of bleomycin-induced pulmonary fibrosis. Eur Respir J 2022; 59(5): 2100864.

PDF (4776KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉